The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...
Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...
The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some ...
The FDA has approved Calquence (acalabrutinib) for use in combination with bendamustine and rituximab to treat adults with previously untreated MCL who are ineligible for transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback